Time Trends and Predictors of Gout Remission Over 6 Years

Le résumé fourni par la source

OBJECTIVE: This study aims to describe the trends in remission rates over 6 years of follow-up among people with gout taking urate-lowering therapy (ULT) and to identify variables that predict remission. METHODS: A post hoc analysis was conducted using data from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial, which enrolled people with gout and cardiovascular disease randomized to febuxostat or allopurinol. Gout remission over 6 years of follow-up was measured in participants with at least 1 year of follow-up data using the simplified gout remission definition, requiring the fulfillment of three domains: (1) no gout flares during the past year, (2) at least two serum urate measurements <0.36 mmol/L during the past year, and (3) no tophus. Logistic regression was used to identify baseline predictors of remission. RESULTS: Achievement of remission increased from 37.4% of participants (1,593/4,259) at year 1 to 63.1% (322/510) at year 6. Over the 6 years, 59.4% of participants achieved remission at least once. More participants receiving febuxostat achieved remission during the first 2 years, primarily because of a higher number achieving the serum urate remission domain. In multivariable analysis, baseline age, race, greater disease severity, presence of comorbidities, and febuxostat treatment were variables significantly associated with remission. CONCLUSION: On ULT, fulfillment of remission increases over time and remission can be achieved in most patients. Baseline predictors, including demographics, comorbidities, and disease severity, may be useful to identify people with gout who need more proactive management to achieve remission.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.